Lv21
140 积分 2021-11-21 加入
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
4天前
已完结
Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system
6天前
已完结
IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
7天前
已完结
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
26天前
已完结
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India
1个月前
已完结
Better by design: What to expect from novel CAR-engineered cell therapies?
1个月前
已完结
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
1个月前
已完结
Current understanding and management of CAR T cell-associated toxicities
2个月前
已完结
CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma
2个月前
已完结
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
2个月前
已完结
皖公网安备34019202002308
